Related Experiment Videos
Tetrapeptide CCK agonists: structure-activity studies on modifications at the N-terminus
R L Elliott1, H Kopecka, M J Bennett
1Department 47W, Abbott Laboratories, Abbott Park, Illinois 60064.
Journal of Medicinal Chemistry
|January 21, 1994
Summary
Researchers optimized novel tetrapeptide cholecystokinin-A (CCK-A) agonists for potential clinical use. Analogs showed potent anorectic activity and maintained CCK-A receptor selectivity, suggesting improved drug candidates.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Drug Discovery
Background:
- Previous work identified potent and selective tetrapeptide cholecystokinin-A (CCK-A) agonists with anorectic properties.
- The lead candidate, A-71623, showed promise but required optimization for clinical development.
Purpose of the Study:
- To optimize the potency, selectivity, stability, and efficacy of CCK-A agonists.
- To explore novel analogs by systematically replacing the N-terminal Boc group of the lead compound.
Main Methods:
- Synthesis of a series of tetrapeptide analogues.
- Systematic replacement of the N-terminal Boc functionality with various chemical groups (amides, ureas, carbamates, sulfonamides).
- Evaluation of CCK-A receptor binding affinity, selectivity, and in vivo anorectic activity in rats.
Main Results:
- The synthesized analogues generally maintained high potency and selectivity for the CCK-A receptor.
- Anorectic activity in rats was preserved or enhanced in the new analogues.
- Several analogues demonstrated comparable or superior activity to the lead compound A-71623.
Conclusions:
- Modification of the N-terminal group can yield analogues with improved drug-like properties.
- These optimized analogues represent promising candidates for further clinical investigation as anti-obesity agents.
- The study highlights the potential of CCK-A agonists in managing appetite and weight.